N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis

Ellard, 1976, J Pharmacokinet Biopharm, Pharmacokinetics of isoniazid metabolism in man, 83

Kinzig-Schippers, 2005, Antimicrob Agents Chemother, Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?, 1733

Azuma, 2013, Eur J Clin Pharmacol, NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy, 1091

Ramachandran, 2012, Pharmgenomics Pers Med, Role of pharmacogenomics in the treatment of tuberculosis: a review, 89

Singh, 2009, Mol Diagn Ther, Study of NAT2 gene polymorphisms in an Indian population: Association with plasma isoniazid concentration in a cohort of tuberculosis patients, 49

Zabost, 2013, Biomed Res Int, Correlation of N-acetyltransferase 2 genotype with isoniazid acetylation in Polish tuberculosis patients, 853602

TB India 2011. Revised National TB Control Programme Annual Status Report. New Delhi: Central TB Division, Government of India; 2011.

Hemanth, 2012, SAARC J Tuberc Lung Dis HIV AIDS, Simple and rapid liquid chromatography method for simultaneous determination of isoniazid and pyrazinamide in plasma, 13

Kuznetsov, 2009, Bioinformatics, A web server for inferring the human N-acetyltransferase-2 (NAT2) enzymatic phenotype from NAT2 genotype, 1185

Jain, 2007, Cancer Invest, Association of genetic polymorphisms of N-acetyltransferase 2 and susceptibility to esophageal cancer in North Indian population, 340

Srivastava, 2005, BMC Urol, Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: A pilot study in North Indian population, 12

Arif, 2007, Clin Chim Acta, Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease, 37

Anitha, 2003, Int J Mol Med, Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India, 125

Chen, 2006, Clin Chim Acta, The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients, 104

Ellard, 1976, Clin Pharmacol Ther, Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis, 610

Hiratsuka, 2002, Drug Metab Pharmacokinet, Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients, 357

Wang, 2012, Int J Tuberc Lung Dis, NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: A meta-analysis, 589

Kubota, 2007, Eur J Clin Pharmacol, Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2, 927

Selkon, 1961, Bull World Health Organ, Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis 2.Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS, 779

Alsultan, 2014, Drugs, Therapeutic drug monitoring in the treatment of tuberculosis: An update, 839